drugset / Trial / NCT01392703

Pharmacokinetic Study Comparing Blood Levels of Dasatinib in Healthy Participants Who Received the Tablet Formulation With Those Who Received Liquid and Tablet-dispersed Formulations

NCT01392703

Phase 1 Completed 141 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-label

Summary

The purpose of the study is to compare the blood levels of dasatinib in healthy participants who received tablet formulation with those of healthy participants who received liquid and tablet-dispersed formulations of the drug.

Timeline

Start
2011-07
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject dasatinib anhydrous Small molecule 100 mg Oral

Indications

No indication recorded.